Pharvaris shares surge as treatment for severe swelling meets clinical trial goal
Shares of Pharvaris N.V. (PHVS) jumped 40% premarket on Wednesday after the Switzerland-based company said an investigational drug met its primary goal in a clinical trial for treatment and prevention of hereditary angioedema attacks. The attacks can cause rapid and severe swelling of the face, windpipe, hands, feet and other areas. The treatment, deucrictibant, significantly reduced the average monthly attack rate, compared to placebo, and cut moderate and severe attacks by 92%, Pharvaris said. Leerink Partners analysts said in a report Wednesday that the result "exceeds expectations" and potentially positions deucrictibant more favorably than BioCryst Pharmaceuticals Inc.'s (BCRX) hereditary angioedema treatment Orladeyo, which has been selling well. Pharvaris shares have gained 86% in the year to date, while the S&P 500 is up 19%. BioCryst shares dropped 4.6% premarket Wednesday and have fallen 46.6% so far this year.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-06-23 0812ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Q3 2024 Stock Market Outlook: Is the AI Stock Trade Over?
-
Ian Bremmer: 4 Big Geopolitical Risks to Watch
-
What’s Happening In the Markets This Week
-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What a Strong Economy Now Means for the Rest of 2024
-
10 Top Dividend Stocks for 2024
-
Finding Small-Cap Stock Opportunities In a Big-Cap World
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks